Regeneron Pharmaceuticals (REGN) implied price
REGN at 16.3x EV/EBITDA implies $728.18 per share.
Using its own 5-year median. 9.6% below the $805.67 weekly close. Week of Oct 19, 2026. Results hold financial inputs fixed.
x
Change the multiple to test a scenario.
Implied price per share
$728.18
USD. A scenario, not a price target.
Compare assumptions
| Reference | EV/EBITDA | Implied price |
|---|---|---|
| 18.2x | $805.67 | |
| 16.3x | $728.18 | |
| 21.3x | $934.07 |
How this price is calculated
Assumed EV/EBITDA × EBITDA per share − net debt per share = implied price. Enterprise value includes debt and subtracts cash.
Multiple labels are rounded to one decimal; calculations use the full value in the input. Inputs are inferred from the same weekly close and rounded multiples used in valuation history. This keeps the comparison on one observation and avoids mixing in later filings. Financial results and net debt are held constant. The median is the middle reading; peer medians exclude REGN.